Oncology Products Benefit Most From Informal Scientific Advice By EMA-FDA Pediatrics 'Cluster'
This article was originally published in SRA
Executive Summary
A relatively new collaboration - under which the European Medicines Agency and the US Food and Drug Administration join forces to issue informal parallel scientific advice to developers of selected pediatric medicines that are under review at both agencies - has so far benefited oncology and gastroenterology products the most.